PROTALIX BIOTHERAPEUTICS INC's ticker is PLX and the CUSIP is 74365A101. A total of 33 filers reported holding PROTALIX BIOTHERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 1.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $913,000 | -55.0% | 4,450,473 | +2.9% | 0.00% | -50.0% |
Q2 2019 | $2,029,000 | +14.8% | 4,326,528 | +7.7% | 0.00% | 0.0% |
Q1 2019 | $1,768,000 | +53.5% | 4,017,705 | +8.5% | 0.00% | +100.0% |
Q4 2018 | $1,152,000 | -51.5% | 3,702,967 | +13.4% | 0.00% | -50.0% |
Q3 2018 | $2,374,000 | +0.1% | 3,266,401 | -33.7% | 0.00% | +100.0% |
Q2 2018 | $2,371,000 | +90.1% | 4,924,200 | +113.2% | 0.00% | 0.0% |
Q1 2018 | $1,247,000 | -5.4% | 2,309,500 | +15.9% | 0.00% | 0.0% |
Q4 2017 | $1,318,000 | +8.1% | 1,993,500 | -5.1% | 0.00% | 0.0% |
Q3 2017 | $1,219,000 | -36.7% | 2,101,300 | -8.7% | 0.00% | -50.0% |
Q2 2017 | $1,927,000 | -26.5% | 2,300,800 | +19.4% | 0.00% | -50.0% |
Q1 2017 | $2,621,000 | +1130.5% | 1,927,500 | +302.1% | 0.00% | – |
Q4 2016 | $213,000 | +106.8% | 479,300 | +165.0% | 0.00% | – |
Q3 2016 | $103,000 | +56.1% | 180,900 | +75.8% | 0.00% | – |
Q2 2016 | $66,000 | +43.5% | 102,900 | +87.4% | 0.00% | – |
Q1 2016 | $46,000 | +119.0% | 54,900 | +162.3% | 0.00% | – |
Q4 2015 | $21,000 | – | 20,933 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 13,275,000 | $13,541,000 | 0.88% |
Broadfin Capital, LLC | 3,338,570 | $3,405,000 | 0.21% |
Spark Investment Management LLC | 229,600 | $234,000 | 0.03% |
Baillie Gifford | 6,406,099 | $6,534,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 349,546 | $357,000 | 0.01% |
A.R.T. Advisors, LLC | 80,108 | $81,000 | 0.00% |
Psagot Value Holdings Ltd. | 101,876 | $103,000 | 0.00% |
WEDBUSH SECURITIES INC | 18,000 | $18,000 | 0.00% |
TFS CAPITAL LLC | 31,234 | $32,000 | 0.00% |
VAN ECK ASSOCIATES CORP | 106,208 | $108,000 | 0.00% |